Listed by the USPTO as GAO, ASHLEY HARTMAN
Tech Center 1700 • Art Units: 1644 1646 1674 1678 1783
This examiner grants 56% of resolved cases
GAO, ASHLEY HARTMAN is assigned to tech center 1700 and art unit 1644. The dataset includes 92 resolved cases, with an allowance rate of 56.5% and a median of 1240 days to allowance. The allowance figure reflects a contested record, and the timing figure indicates that successful matters may require extended prosecution. Interviews have a 38.0% lift, giving applicants a substantial measured reason to prepare for direct discussion of technical and claim issues.
The leading companies are Genentech Inc., INCYTE Corporation, and Hoffmann-La Roche Inc. The principal firms are FISH & RICHARDSON P.C. (TC), WENDEROTH, LIND & PONACK, L.L.P., and BAKER BOTTS L.L.P. This mix provides relevant context for biotechnology matters. Counsel should combine interview preparation with precise amendments and evidence addressing the cited references.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17199195 | CSF-1R ANTIBODY FORMULATION | Final Rejection | Hoffmann-La Roche Inc. |
| 17776131 | SYSTEMS AND METHODS FOR RAPID, SENSITIVE MULTIPLEX IMMUNOASSAYS | Final Rejection | The Regents of the University of Michigan |
| 18808311 | BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 16961026 | Fusion Protein Extensions | Final Rejection | NantBio, Inc. |
| 18104825 | T CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY | Non-Final OA | GENENTECH, INC. |
| 17168621 | USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION | Final Rejection | Genentech, Inc. |
| 18843878 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18245868 | IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18265661 | FEATURES FOR DETERMINING DUCTAL CARCINOMA IN SITU RECURRENCE AND PROGRESSION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18560223 | CONTROL SLIDE GLASS FOR PATHOLOGICAL EXAMINATION AND METHOD FOR MANUFACTURING SAME | Final Rejection | Hitachi High-Tech Corporation |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | Non-Final OA | Juno Therapeutics, Inc. |
| 18435746 | TIGIT AND CD112R BLOCKADE | Non-Final OA | AMGEN INC. |
| 16980128 | IMMUNO-EXOSOMES AND METHODS OF USE THEREOF | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18180991 | SYSTEMS AND METHODS FOR PREDICTING GRAFT DYSFUNCTION WITH EXOSOME PROTEINS | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17289970 | METHOD FOR PRODUCING PLURIPOTENT STEM CELL HAVING RELEASED DIFFERENTIATION RESISTANCE TO MESENDODERM | Final Rejection | Kyoto University |
| 17641473 | ASSAY FOR IMMUNE CELL RECOVERY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 17294327 | METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS | Final Rejection | BIOASTER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.5% of resolved applications examined by Ashley Hartman Gao were allowed (92 resolved cases), compared with 35.9% across Art Unit 1644 over the last five years.
This examiner's interview lift is +38.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ashley Hartman Gao took 1,240 days on average from filing to allowance.
Ashley Hartman Gao examines applications in Art Unit 1644 in Tech Center 1700 (Chemistry & Materials).
